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Abstract
Background: Atypical expression of cell cycle regulatory proteins has been implicated in Alzheimer’s disease (AD),
but the molecular mechanisms by which they induce neurodegeneration are not well understood. We examined
transgenic mice expressing human amyloid precursor protein (APP) and presenilin 1 (PS1) for changes in cell cycle
regulatory proteins to determine whether there is a correlation between cell cycle activation and pathology
development in AD.
Results: Our studies in the AD transgenic mice show significantly higher levels of cyclin E, cyclin D1, E2F1, and P-
cdc2 in the cells in the vicinity of the plaques where maximum levels of Threonine 668 (Thr668)-phosphorylated
APP accumulation was observed. This suggests that the cell cycle regulatory proteins might be influencing plaque
pathology by affecting APP phosphorylation. Using neuroglioma cells overexpressing APP we demonstrate that
phosphorylation of APP at Thr668 is mitosis-specific. Cells undergoing mitosis show altered cellular distribution and
localization of P-APP at the centrosomes. Also, Thr668 phosphorylation in mitosis correlates with increased
processing of APP to generate Ab and the C-terminal fragment of APP, which is prevented by pharmacological
inhibitors of the G1/S transition.
Conclusions: The data presented here suggests that cell cycle-dependent phosphorylation of APP may affect its
normal cellular function. For example, association of P-APP with the centrosome may affect spindle assembly and
cell cycle progression, further contributing to the development of pathology in AD. The experiments with G1/S
inhibitors suggest that cell cycle inhibition may impede the development of Alzheimer’s pathology by suppressing
modification of bAPP, and thus may represent a novel approach to AD treatment. Finally, the cell cycle regulated
phosphorylation and processing of APP into Ab and the C-terminal fragment suggest that these proteins may have
a normal function during mitosis.
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Background
The major pathological characteristics of Alzheimer’s
disease are the presence of neuritic plaques and neurofi-
brillary tangles (NFT) in the affected areas of the brain
[1-3]. In addition, AD brains show neuroinflammation
and neuronal loss, which is associated with aberrant
expression of cell cycle regulatory proteins [4-8]. The
cause or the function of the increased levels of cell cycle
regulatory proteins in post-mitotic neurons is not clearly
understood. Studies by different groups suggest that
fully differentiated neurons in adult brains emerge from
quiescence and attempt to re-enter the cell cycle under
pathological conditions [4,8-23]. This apparent upregu-
lation of cell cycle regulatory proteins in neurons, along
with the findings that the inhibitors of cell cycle activa-
tion protect neurons from undergoing apoptosis, led to
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to re-enter the cell cycle may lead to neurodegeneration
and apoptosis [6,12,24-32]. In addition to neuronal loss,
it is possible that dysregulation of the cell cycle may
lead to cell cycle-dependent modifications in the amy-
loid precursor protein (APP) and tau, the two major
proteins associated with AD, favouring plaque and tan-
gle formation and neurodegeneration in the AD brains.
APP is a single transmembrane protein that is sequen-
tially cleaved by b and g- secretases to generate the Ab
peptide, which gets deposited extracellularly to form
plaques and vascular amyloid deposits [33]. Mutations
in APP and presenilin 1 (PS1) are associated with
increased generation of Ab and increased pathology
development in AD [34]. In addition to the accumula-
tion of Ab into amyloid, studies in neurons have shown
that Ab peptides can induce cell cycle activation and
neuronal apoptosis [35]. Expression of a mutant form of
A P Po rP S 1 ,a sw e l la st r e a t m e n tw i t hA b,h a v eb e e n
shown to induce chromosome mis-segregation and
aneuploidy in cells [36,37], which indicates aberrant cell
cycle activation under these conditions. Studies con-
ducted in two different AD mouse models have shown
an upregulation of cell cycle regulatory proteins in glial
cells [38] and neurons [39]. Thus, cell cycle deregulation
may influence both neuronal and glial functions, and a
keen analysis of the cell cycle-dependent changes in
these cells may reveal the significance of the upregulated
expression of cell cycle markers in AD brains. Mice gen-
erally do not show much neuronal loss, but it is possible
that the upregulation of cell cycle regulatory proteins
may mediate synaptic loss and neurodegeneration by
inducing modifications in tau and APP. Here we ana-
lyzed the specific effects of cell cycle activation on APP
modifications.
APP is phosphorylated by multiple kinases, which
affects its proteolytic processing, trafficking, and
protein-protein interaction [40-48]. We tested the
hypothesis that cell cycle activation can affect APP mod-
ifications and plaque development, using in vitro cul-
tured cells and transgenic mice. The studies presented
here show that transgenic mice expressing mutant APP
(APPV717F) and PS1 (PS1M146L) show an increase in the
levels of cell cycle regulatory proteins which is asso-
ciated with induction of APP phosphorylation at Thr668
and formation of Ab and phosphorylated C-terminal
fragment of APP. Experiments conducted in H4 neuro-
glioma cells overexpressing APP confirmed that this
phosphorylation is mitosis-specific and can be inhibited
by G1/S transition inhibitors, which prevent Ab genera-
tion. A role for G1/S specific inhibition was further
determined by inhibition of P-APP formation by siRNA
to cdk-2. This observation, along with our finding that
P-APP co-localizes with MPM2 at centrosomes in
mitotic cells suggests that mitotic mechanisms may
influence AD pathology by not only affecting APP phos-
phorylation and Ab generation, but also by enabling it
to have a role in spindle assembly and cell cycle regula-
tion. Thus, APP may act as a cell cycle inducer under
mitotic conditions and might play a feed forward role in
pathology development in AD.
Results
Upregulation of cell cycle regulatory proteins in AD
transgenic mice
Atypical expression of cell cycle regulatory proteins has
been shown primarily in neurons of AD brains. Studies
in different mouse models of AD showed upregulation
of cell cycle regulatory proteins with some variation in
t h eo b s e r v a t i o n s ;w h i l eo n estudy showed upregulation
of cyclins D1, B and E in astrocytes with cdk4 nuclear
translocation [38], another study showed upregulation of
PCNA and cyclin A in neurons [39]. Because there is
variation in cell cycle protein expression in different AD
transgenic mice, we tested the transgenic mice that we
used in our studies for changes in the reported cell
cycle regulatory proteins. The brains from 12 month old
mice expressing mutant human APP (V717F), mutant
PS1 (M136L), a combination of these two transgenes,
and age matched non-transgenic (Ntg) controls were
analyzed by quantitative immunohistochemistry using
specific antibodies to cyclin D1, cyclin E, E2F1, P-cdc2,
and cdc2. Significant increases in cyclin D1, cyclin E, P-
cdc2, and E2F1 were observed in the PS/APP double
transgenic mice (Figure 1A and 1B). Mice expressing
APP alone showed a smaller increase in the level of
these cell cycle regulatory proteins compared to the
double transgenic mice (Figure 1A, d compared to 1A,
e), possibly due to the differences in the transgene
expression and the fact that PS/APP mice develop
pathology at an earlier age compared to APP expressing
mice. E2F1 and cyclin E stained cells surrounding the
plaques (Figure 1A, inset b, d, and e) appeared to have
glial-like morphology, whereas P-cdc2 appeared to stain
both neuronal and glial-like cells (Figure 1A, g: black
arrow head - neuron & white arrow head - glia). We did
not observe any change in the level of staining with a
non-phospho-cdc2 antibody. Figure 1B shows the quan-
titative analysis of cyclin D1 and E levels in APP and
PS/APP mice compared to Ntg mice. Co-immunostain-
ing analysis of brains from 10 month old PS/APP mice
with cyclin D1 or cyclin E and 6E10 antibodies showed
increased levels of these cell cycle regulatory proteins in
neurons in the brains (Figure 2A and 2B). Studies from
other groups have shown that Ab can induce neurode-
generation through activation of cell cycle dependent
mechanisms [49,50]. Further studies are necessary to
determine whether the increased expression of cell cycle
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increased levels of Ab in the AD transgenic brains. It is
possible that the cell cycle activation and Ab generation
are regulated in a feed forward manner, with cell cycle
activation inducing Ab production and Ab in turn indu-
cing cell cycle deregulation.
Phosphorylation of APP at Thr668 in mice expressing AD
transgenes
APP is a transmembrane protein and is phosphorylated
by several kinases including the cell cycle-dependent
kinase cdc2 [45]. Phosphorylation of APP seems to
enhance its proteolytic processing and altered localiza-
tion [42,43]. In order to determine the phosphorylation
levels of APP in cells associated with AD pathology, we
performed immunohistochemical and western blot ana-
lysis of brain samples from mice expressing PS1 or APP
alone or together and compared the results to that from
age-matched Ntg mice. Co-staining with the Ab anti-
body (6E10) and Thr668 specific P-APP antibody (P-
Thr668-APP) showed that significantly higher levels of
P-APP and Ab (6E10 positive) associate with the pla-
ques in AD mice (Figure 3). The Ab staining (6E10) was
localized mostly to the plaque cores with some diffuse
staining around the plaques whereas P-APP was distrib-
uted towards the periphery of the plaques.
The staining pattern observed with Thr668 P-APP
antibody around the plaques suggested that P-APP is
accumulating in dystrophic neurites. In order to confirm
this, we performed co-staining of the sections with anti-
bodies specific for P-APP and phosphorylated neurofila-
ment H protein (NF-H, SMI34) (Figure 4). SMI34 stains
neurofilament proteins when phosphorylated, and it has
been shown to stain NFTs and dystrophic neurites [51].
We found co-localization of SMI34 and P-APP in the
areas surrounding the plaques in APP and PS/APP mice
(Figure 4, rows 3 and 4), suggesting the association of
Thr668 P-APP with degenerating neurites. Ntg mice
and PS1 mice did not show any specific staining with
either Thr668 P-APP or SMI34 antibodies (Figure 4,
rows 1 and 2).
APP phosphorylation and processing in AD
transgenic mice
Western blot analysis of brain extracts from transgenic
mice using the human specific 6E10 (raised against
Figure 1 Increased expression of cell cycle regulatory proteins in AD transgenic mice: A) Cyclin E, E2F1 and P-cdc2 levels are upregulated
in transgenic mice expressing APP and PS/APP: Brain sections from Ntg normal mice (a, c, f) were compared to those from transgenic mice
expressing APP (d, g) and PS/APP (b, e, h) using cyclin E (upper panel), E2F1 (middle panel) or P-cdc2 (lower panel) antibodies. Images (a-e, 5×
and f-h 20×) were taken using a Nikon E1000 microscope and analyzed using Image-Pro Plus software. The P-cdc2 and images in the inset show
magnified images (20×) of the plaques to visualize the cells. We found that the cells surrounding the plaques were positive for cyclin E, E2F1,
and P-cdc2, and it appears that both neurons (black arrow head) and glia (white arrow head) were positive for P-cdc2. ‘Secondary antibodies
only’ control did not show any specific staining of the sections (data not shown). B) Quantitative analysis of cyclin D1 and E expression in APP
and PS/APP transgenic mice brains: Brain sections from Ntg and mice expressing APP and PS/APP were stained using a monoclonal cyclin D1 or
a polyclonal cyclin E antibody and nuclei visualized using Hoechst. The signal intensity was measured using Image J, image processing and
analysis program. The signal strength was compared to that with Hoechst nuclear staining from each section to avoid mouse-to-mouse
variation. The means of results from six independent mice are shown with standard error bars and P values. While APP mice showed a
significantly higher level of only cyclin E compared to cyclin D1, PS/APP mice showed higher levels of both cyclin D1 and E levels
compared to Ntg.
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expression of APP in both APP and PS/APP transgenic
mice (Figure 5A). As 6E10 is more specific for human
APP, for detection of mouse APP the blots were
reprobed with C-APP antibody, which showed the total
expression level of APP in vivo in the non-transgenic
a n dt r a n s g e n i cm i c e( F i g u r e5 C ) .T h et r a n s g e n i cm i c e
expressing APP and PS/APP showed very high levels of
C-terminal APP fragments (Figure 5A and 5C). 6E10
antibody detected Ab in both APP and PS/APP mice
(Figure 5A). The level of Ab showed variation between
mice probably due to the altered levels of transgene
expression. Examination of blots using Thr668 P-APP
antibody showed that both full length and C-terminal
fragment of APP show significantly higher levels of
Thr668 phosphorylation compared to that detected in
non-transgenic and PS1 mice (Figure 5D). This finding,
along with the finding that in primary rat neurons the C-
terminal fragment generated by BACE cleavage shows
more phosphorylation at Thr668 than does a-secretase
cleaved C-APP [42], suggests that the amyloidogenic clea-
vage of APP is enhanced upon phosphorylation at
Thr668. The Thr668 P-APP antibody detects APP only
when phosphorylated at Thr668 [40] and has been shown
to react with human, mouse, and rat P-APP (Cell Signal-
ing Technologies). On the western blot, it detected the
intracellular levels of P-APP in the mouse (Ntg and PS),
but the levels in APP expressing mice were significantly
higher. The histograms in Figure 5E, F and 5G show the
percent of P-APP (full length, C-terminal fragment, and
total) compared to the total counterpart of APP detected
by the C-terminal antibody, in the brain extracts.
Figure 2 AD transgenic mice show increased expression of cyclin D and cyclin E in neurons: Brain sections from 10 month old Ntg and
PS/APP mice were co-stained using A) monoclonal 6E10 and polyclonal cyclin D1 or B) 6E10 and polyclonal cyclin E antibodies. Staining was
visualized using Alexa fluor 488 (APP and Ab, green) and Alexa fluor 594 (red) and analyzed under a Zeiss microscope using AxioVision Rel 4.8.
The images were taken at 20× magnification. The composite image shows staining with Hoechst, cyclin, and 6E10 antibodies. The area indicated
by arrows is enlarged and shown on the right to clearly see the positive staining in neurons.
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phosphorylation of APP in transgenic mice
The above results showed that APP phosphorylation and
processing are enhanced in transgenic mice expressing
APP. In order to determine whether the APP phosphor-
ylation varies with age, we examined transgenic mice
expressing APP and PS/APP at different ages. Brain
e x t r a c t sw e r ep r e p a r e df r o mm i c ea t1 . 5 ,2 ,3a n d6
months of age and western blotted using Thr668 P-APP
and 6E10 Antibodies (Figure 6A-G). As expected, it was
found that the total levels of APP and C99 fragments
(using 6E10 antibody) were significantly higher in the
AD transgenic mice (APP and PS/APP) compared to the
non-transgenic mice. Within the transgenic groups, we
did not observe any age-dependent increase in the levels
of full length APP or C-99 fragments (Figure 6A and
6D). On the other hand, the transgenic mice showed an
age-dependent increase in Ab generation, with the mice
expressing PS/APP showing higher levels of Ab than
that expressing just APP (Figure 6A and 6G). Expression
levels of full length P-APP did not vary significantly with
age whereas the levels of phosphorylated C-terminal
fragments (P-C-APP) were increased in an age-depen-
dent manner in the AD mice (Figure 6B and 6E). Figure
6F shows the levels of Ab compared to full length APP
i nt h et r a n s g e n i cm i c e ,a n dF i g u r e6 Gs h o w st h el e v e l s
of Ab compared to the levels of P-C-APP. A reprobe of
the APP blots using actin antibody showed equal
amounts of proteins on the blot (Figure 6C). It is known
that pathology development in AD is age-dependent.
The data presented here further demonstrates that APP
phosphorylation and processing as well as Ab generation
are also age-dependent and these fragments may contri-
bute to the enhanced pathology development in AD.
In order to determine the localization of P-APP in
mice at different ages we examined the brains from 1.5
and 6 month old mice using Thr668 P-APP and 6E10
antibodies. 1.5 month old APP and PS/APP mice
showed a general increase in overall staining and an
association of P-APP with degenerating (beaded) neur-
ites (Figure 7A, B shows enlarged images of beaded
neurites in APP and PS/AP mice). 6E10 staining was
mainly visible within the neuronal cell bodies of APP
and PS/APP mice (Figure 7A). At 6 months of age the
APP mice showed accumulation of P-APP in some neu-
rons without any plaque pathology (Figure 7D, B shows
neurons that show accumulation of P-APP). Unlike APP
mice, 6 month old PS/APP mice showed very strong
localized accumulation of P-APP in plaque-like struc-
tures, which did not always relate with 6E10 stained pla-
ques (Figure 7D, E shows the enlarged image of the area
indicated by arrows in PS/APP mice).
Cell cycle-dependent phosphorylation of APP
The phosphorylation of APP at Thr668 in transgenic
mice correlated with the expression of cell cycle
Figure 3 APP overexpressing mice show increased levels of Thr668 P-APP: Brain sections from Ntg, APP, and PS/APP mice were
immunostained using monoclonal 6E10 antibody and polyclonal Thr668 specific P-APP antibody. A: Representative sections from Ntg (top row),
APP (middle row), and PS/APP (bottom row) mice stained with a 6E10 antibody (left column), Thr668 P-APP antibody (middle column) and
composite image (right column) with Hoechst showing nuclear staining. Magnification: 40×. B: Quantification of the intensity of 6E10 and P-APP
staining in Ntg, APP, PS/APP and PS mouse brains. Both APP and PS/APP mice showed significantly higher levels of APP and Thr668 P-APP with
more intensity in mice expressing both PS and APP transgenes compared to APP alone. The Ntg and PS expressing mice showed low levels of
APP and P-APP.
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with the published findings [45], prompted us to deter-
mine whether the APP phosphorylation is due to cell
cycle activation. Since it is difficult to verify this in vivo,
we decided to examine APP phosphorylation in cells
cultured in vitro. H4 neuroglioma cells overexpressing
WT-APP (H4-APP) were cultured for 24 hr and serum
starved for 48 hr. At the end of the starvation period,
cells were serum stimulated in the presence or absence
of pharmacological inhibitors of cell cycle progression
for different time periods, and cell extracts were immu-
noprecipitated using 6E10 antibody and analyzed using
P-APP antibody. The treatment of the cells included
roscovitine (20 μM for 12-14 hr) an inhibitor of cdk2,
cdc2, and cdk5 [52], olomoucine (50 μM for 12-14 hr)
an inhibitor of cdk1 (cdc2), cdk2, and cdk5 [53], aphidi-
colin an S-phase inhibitor (5 μg/ml for 12-14 hr), or the
mitotic inhibitors nocodazole (100 ng/ml), vinblastine
Figure 4 Thr668 P-APP antibody co-localizes with phospho-neurofilament NFH antibodies in the plaques: Brain sections from Ntg, PS,
APP, and PS/APP mice were analyzed with Thr668 P-APP and monoclonal P-NFH (SMI34) antibodies and visualized using Alexafluor 594 and 488
respectively. Nuclei were visualized using Hoechst stain. Magnification: 40×.
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of the cells using a fluorescence activated cell sorter
(FACS) showed that roscovitine and aphidicolin treated
cells were mostly arrested in the G1 phase of the cell
cycle (60-70%), while nocodazole arrested cells were
mostly in the G2/M phase (Figure 8E). Cell extracts
after treatment were immunoprecipitated using 6E10
antibody and the blot was analysed using P-APP anti-
body. We found that Thr668 specific phosphorylation
on APP was induced in a time dependent manner upon
serum stimulation, and maximum levels of phosphoryla-
tion occurred upon mitotic arrest using nocodazole or
vinblastine (Figure 8A and 8D). The total levels of APP
(reprobe using 6E10 antibody) also showed a similar
profile, but the levels were not as significant as those we
observed with P-APP (Figure 8B). Reprobe of blots
using actin antibody (without stripping) showed
approximately equal amounts of proteins on the gel
(Figure 8C). Roscovitine treatment consistently resulted
in a decrease in the levels of P-APP, and aphidicolin
and olomoucine kept the phosphorylation more or less
at the basal levels (Figure 8A and 8D). These data con-
firm that the Thr668 specific phosphorylation on APP
occurs in a cell cycle-dependent manner and peaks dur-
ing mitosis. Cells treated for 16-18 hr with taxol, a
microtubule stabilizing agent, largely accumulated in the
G1 (~45-50%) and G2 (~40-45%) phases, which was
similar to that observed with serum stimulation for 16
hr and showed slightly higher levels of P-APP compared
to serum stimulated cells. The results from the time
course with serum as well as treatment with roscovitine,
olomoucine, and aphidicolin suggest that APP phos-
phorylation occurs very early during the cell cycle.
Thus, it is possible that in the brains of transgenic mice
APP phosphorylation arises from cells attempting to
enter the cell cycle and inhibitors of G1/S checkpoint
may inhibit this phenomenon.
si-cdk2 inhibits serum stimulation-induced APP
phosphorylation in H4-APP cells
We found that APP is phosphorylated at Thr668 in a
cell cycle-dependent manner and that roscovitine, an
inhibitor of cdks such as cdc2, cdk2, and cdk5, pre-
vented both APP phosphorylation and Ab generation
while nocodazole, a mitotic inhibitor, induced these
phenomena. Earlier studies had shown that both cdk5
and cdc2 could induce Thr668 specific phosphorylation
of APP while nothing was known about cdk2. In order
to determine whether cdk2 or cdk4 are involved in APP
phosphorylation during mitosis, we transfected H4-APP
cells with different concentrations of cdk2 and cdk4
siRNA and analyzed for changes in APP after 16 to 18
Figure 5 Increased levels of APP phosphorylation and processing in transgenic mice expressing APP and PS/APP: Equal amounts of
proteins from Ntg, APP, PS1, and PS/APP brain extracts were analyzed using 6E10, C-APP, 22C11, and P-Thr668 APP antibodies. A) Shows
western blot analysis using monoclonal 6E10 antibody (detect APP, Ab, and any Ab containing fragments of APP), B) shows reprobe of the same
blot using actin antibody (indicated by arrow) without stripping to show equal amounts of protein loading, C) western blot using a polyclonal
C-terminal APP antibody (detects full length and C-terminal fragments of APP), and D) represents the western blot using Thr668 P-APP antibody.
Mice expressing APP and PS/APP showed very high levels of full length and C-terminal APP fragments. Ab levels showed mouse-to-mouse
variation probably due to varied expression of the transgenes. Levels of P-APP were significantly higher in both APP and PS/APP transgenic mice
and the antibody detected the phosphorylated C-terminal fragment of APP as well. Blots were analyzed using supersignal ECL solution from
Pierce. The histograms represent quantitative analysis of P-APP compared to the corresponding counterpart of total APP detected using C-
terminal APP antibody: E) percent of full length P-APP, F) percent of P-C-APP (phosphorylated C-terminal fragment), and G) percent of total P-
APP compared to total APP.
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Page 7 of 20Figure 6 Age-dependent changes in Thr668 specific phosphorylation and Ab generation in transgenic mice: Brain extracts from 1.5, 2, 3,
and 6 month old Ntg mice and transgenic mice expressing APP and PS/APP were examined by western blot using Thr668 P-APP and 6E10
antibodies. Panel A shows the levels of full length APP and fragments of APP such as C-99 and Ab in the mice at different ages. The transgenic
mice expressing APP and PS/APP showed very high levels of full length APP. Only the levels of Ab were altered in an age-dependent manner.
Panel B shows staining of the blot with Thr668 P-APP antibody, which detects mouse and human APP phosphorylated at this site. The levels of
full length P-APP were higher in the transgenic mice. Levels of phosphorylated C-terminal P-APP fragments were induced in an age-dependent
manner in the transgenic mice. Panel C shows reprobe of the blot with actin antibody without stripping to show approximately equal amount
of protein loading. D-F shows the relative signal intensity of the various APP fragments from the western blot analysis. D) Represents signal
intensity of full-length APP and C-99 fragments, E) that of full length P-APP and phosphorylated C-terminal fragments of P-APP (P-C-APP), F)
represents the levels of APP and Ab and G) shows signal intensity of P-C-APP and Ab.
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Page 8 of 20Figure 7 Immunohistochemical analysis of brain sections from transgenic mice at different ages: In order to determine whether there is
accumulation of P-APP in the brain mice at 1.5 and 6 months were analysed using 6E10 and P-APP antibodies. Brain sections from transgenic
mice showed an increase in overall staining using the 6E10 and P-APP antibodies (A-D). Panel A shows brain sections from 1.5 month old mice
where P-APP showed beaded staining of neurites occasionally in APP and PS/APP mice. 6E10 staining showed APP in the neuronal bodies in
these sections. The enlarged P-APP positive neurites are shown in panel B. Panel C shows examples of neurons in APP mice at 6 months that
show P-APP accumulation. Panel D shows the P-APP and 6E10 staining in 6 month old Ntg, APP, and PS/APP mice. The accumulation of Ab and
P-APP are visible only in the PS/APP mice at 6 months. Panel E shows the magnification of the area shown with the arrows from 6E10 and P-
APP stained PS/APP sections. Images in panel A were taken at 10× and in panel B at 20 × magnifications. Images shown in Panel D were taken
at 5× magnification.
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antibodies confirmed the downregulation of the kinases
in the transfected cells (Figure 9A). Analysis of extracts
from cdk2 downregulated cells showed that this is asso-
ciated with a decrease in APP phosphorylation at
Thr668 (Figure 9A) whereas cdk4 inhibition was not
(data not shown). A non-specific control siRNA did not
have any effect on the kinases or APP phosphorylation,
suggesting that the results we observed with si-cdk2 are
specific to this cdk. In the G1 phase of the cell cycle,
cdk2 associates with cyclin E and enables the transition
of cells through the G1/S checkpoint. The result with
si-cdk2 thus agrees with the results shown in Figure 8
in which APP phosphorylation is induced upon serum
stimulation and is inhibited by blocking the G1/S
transition.
Since it is known that cdk5 as well as GSK-3b can
induce tau hyperphosphorylation in AD brains, and since
these kinases have also been shown to affect APP phos-
phorylation, we examined the effect of downregulation of
these kinases on APP phosphorylation. Cells transfected
with siRNA to GSK-3ab (Figure 9B) and siRNA to cdk5
(Figure 9C) also showed downregulation of APP phos-
phorylation as expected and it correlated with the levels
of down regulation of the corresponding kinases. These
data thus suggest that APP and tau are phosphorylated
Figure 8 Mitosis-specific phosphorylation of APP: H4-15X cells were growth arrested by serum starvation for 48 hr and serum stimulated
with and without roscovitine, olomoucine, or aphidicolin for 12 hr, and nocodazole, vinblastine, or taxol for 16 hr. Cell extracts were prepared
and equal amounts of proteins were immunoprecipitated using 6E10 antibody and western blotted using P-APP antibody (A). B) APP levels in
total lysate analyzed using 6E10 antibody. Panel C shows reprobe of blot B (without stripping) with actin antibody showing equal amount of
proteins on gel. The histogram in panel D shows the percent of P-APP in cells under the different treatment conditions. The data represent the
mean of 3 independent experiments with standard deviation shown. Cells arrested in metaphase showed significantly higher levels of P-APP (P
< 0.05). Panel E shows the FACS analysis data from cells treated with cell cycle inhibitors. Cells were treated with roscovitine or aphidicolin for
12 hr or nocodazole or taxol for 16 hr and fixed and stained using propidium iodide before analysis on a FACS machine. Mean percent of cells
in different phases of the cell cycle from 3 independent experiments is shown.
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kinases should be tested for their ability to reduce devel-
opment of pathology in AD. The G1/S inhibitor roscov-
itine has been shown to inhibit cdk5 and therefore the
effect we see with this inhibitor could be due to its effect
on not only cdk2 but other responsive kinases as well.
Distribution of P-APP in asynchronously growing cells
Our results from H4-APP cells using the pharmacological
inhibitors suggested that G1/S checkpoint inhibition pre-
vents APP phosphorylation at Thr668. This prompted us
to determine the expression and distribution of P-APP in
cells at different phases of the cell cycle. First, we exam-
ined the localization of P-APP in asynchronously growing
H4-APP cells. The cells were trypsinized and cultured for
24 hr and fixed and analyzed with monoclonal a-tubulin
and polyclonal Thr668 P-APP antibodies. As expected,
t h ea s y n c h r o n o u s l yg r o w i n gc u l t u r ec o n t a i n e dan o n -
homogeneous population of cells in different phases of
cell cycle (Figure 10A and 10B). P-APP showed a cell-
cycle specific localization with more staining in cells that
are in active division (prophase, metaphase, anaphase)
and very little or no staining in early interphase cells (Fig-
ure 10A-10C). The cells that were in metaphase showed
prominent localization of P-APP to the centrosomes
(microtubule organizing centers; MTOCs) suggesting a
role for phosphorylated APP in cell cycle activation and/
or spindle assembly. We confirmed the localization of P-
APP to centrosomes in metaphase cells using confocal
microscopy (Figure 11). Cellular distribution of P-APP
was also examined in cells treated with the pharmacologi-
cal inhibitors roscovitine, aphidicolin, nocodazole, or
taxol. While cells treated with roscovitine and aphidicolin
showed very few cells in active division and hence little
P-APP staining, the majority of the nocodazole treated
cells were in the mitotic phase and exhibited significantly
higher levels of P-APP (data not shown).
Evidence for mitotic phosphorylation and centrosome
localization of P-APP
In order to confirm that the phosphorylation of APP at
Thr668 is mitosis-specific, we co-stained cells with
Figure 9 siRNA to cdk2, cdk5, and GSK-3ab inhibits serum stimulation-induced APP phosphorylation at Thr668: H4-APP cells plated in
serum-free OPTI-MEM were transfected with siRNA to cdk2 (Panel A), GSK-3ab (panel B) or cdk5 (Panel C) at the indicated concentrations using
oligofectamine. After 6 hr serum containing media was added to the cells and samples were collected after 24-48 hr. Cell lysates were western
blotted using the corresponding kinase antibodies to confirm downregulation of the respective kinases. Phosphorylation status of APP was
analyzed using P-Thr668 APP antibody, and actin was used as a loading control. Down regulation of each kinase was associated with inhibition
of serum stimulation-induced phosphorylation on APP. The histograms below each blot show the quantification of the level of the respective
kinase and P-APP compared to the levels present in siRNA control transfected cells. The data are representative of one of three independent
experiments.
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The best-characterized antibodies for this purpose are
the metaphase protein monoclonal-2 (MPM2). MPM2
antibodies detect phosphoproteins that are present in
mitotic cells and have been shown to associate with the
kinetochore, centrosome, midbody and fibers of the
mitotic spindle [54]. Our analysis of asynchronously
growing untreated cells showed that, in metaphase, P-
APP co-localized with MPM2 at the centrosomes (Fig-
ure 12 top row). In cells arrested with nocodazole,
although P-APP levels were significantly elevated (Figure
12 bottom row), due to the microtubule destabilizing
function of nocodazole we did not observe any meta-
phase cells with classic spindles and spindle poles. The
high levels of P-APP in these cells correlated well with
the western blot data and confirm that APP is heavily
phosphorylated under mitotic conditions. These results
suggest that the phosphorylation of APP may play a role
in cell cycle dependent processes including centrosome
replication.
Figure 10 Analysis of P-APP distribution in asynchronously growing H4-15X cells show cell cycle-dependent localization of P-APP:
Panels A and B show asynchronously growing H4-15X cells fixed and immunostained using Thr668 P-APP polyclonal and a-tubulin monoclonal
antibodies and visualized using Alexa 594 (red) and 488 (green) fluorophores respectively. Staining was analyzed using the AxioVision Rel 4.8
software for Zeiss microscope. Nuclei were visualized using Hoechst staining. Cells in mitotic phase showed P-APP localized to the centrosomes,
nucleus and cytoplasm with maximum immunoreactivity in mitotic cells and minimum/none in interphase cells. Cells in telophase showed P-
APP staining in the midbody which was absent in cells undergoing cytokinesis. The absence of staining in the interphase cells suggests that APP
phosphorylation at Thr668 occurs only when cells are undergoing division. Panel C shows a cell cycle schematic with representative cells from
different stages of the cell cycle (selected from an asynchronously growing culture) illustrating the phosphorylation event occurring once the
cells enter prophase and tapering off as it exits the cell cycle (cytokinesis). Magnification: 63×.
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and Ab generation
We next examined whether Ab generation is altered in
a cell cycle-dependent manner and whether it parallels
the phosphorylation of APP. Cells were growth arrested
by serum starvation for 48 hr and serum stimulated in
the presence or absence of pharmacological inhibitors
of cell cycle progression for different time periods. The
cell culture supernatants and cell extracts were then
immunoprecipitated and western blotted using the Ab-
specific 6E10 antibody. The results showed that intra-
cellular and secreted levels of Ab increase in a time-
dependent manner upon serum stimulation of growth
arrested cells (Figure 13A-D, C and 13D show the bot-
tom region of the blot from longer exposure to detect
Ab in lysates), and followed a similar profile as in APP
phosphorylation (Figure 8). The histograms in E and F
show the percent levels of Ab in supernatant and lysate
in comparison to the total levels of full length APP in
the respective samples. In the case of cells arrested
with pharmacological agents, the maximum levels of
intracellular and secreted Ab were present in mitosis-
arrested cells (nocodazole, vinblastine, and taxol) with
the lowest levels in the roscovitine treated (G1/S inhib-
ited) cells. Treatment of neurons in vitro with Ab pep-
tide has been shown to induce cell cycle activation and
neuronal apoptosis [27,49]. Thus, these findings not
only imply that APP is phosphorylated and processed
in a cell cycle-dependent manner, but also suggest that
the observed cell cycle activation in the brains of AD
transgenic mice may induce APP phosphorylation,
leading to enhanced levels of intracellular and extracel-
lular Ab that subsequently induce cell cycle activation
and neurodegeneration.
Figure 11 Centrosome association of Thr668 P-APP in mitotic cells: Asynchronously growing H4-APP cells were fixed and immunostained
using Thr668 P-APP polyclonal and a-tubulin monoclonal antibodies and visualized using Alexa 594 (red) and 488 (green) fluorophores
respectively. Nuclei were visualized using Hoechst staining. Staining was analyzed using the FV10-ASW 1.7 software for Olympus confocal
microscope. Cells in metaphase and anaphase showed very clear P-APP localization at the centrosomes. Staining was very weak or absent in the
interphase cells. Magnification: 63×.
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cultured cells, we found that, similar to our observations
in AD transgenic mice, phosphorylation was associated
with increased BACE cleavage of APP, as evident by the
C-terminal fragment detected by the 6E10 antibody. The
C-APP levels were lowest in roscovitine treated G1/S
checkpoint arrested cells. Recent studies using a C-term-
inal fragment of APP have shown that the administration
of this fragment induces apoptosis in cells of neuronal
origin [55]. Thus, our results support the suggestion that
inhibitors of G1/S transition may prevent neurodegenera-
tion by preventing unwarranted processing of APP to
generate neurotoxic Ab and C-APP.
Discussion
Alzheimer’s disease is characterized by the presence of
neuritic plaques and neurofibrillary tangles in the
affected areas of the brain. In addition, AD brains show
considerable neuronal loss and neuroinflammation, the
causal mechanisms of which are under active investiga-
tion. Studies from several laboratories have shown that
AD brains exhibit aberrant upregulation of cell cycle
regulatory proteins [4,6,7,14,22,56]. It is suggested that
the deregulated expression of cell cycle proteins in neu-
rons may contribute to the pathology associated with
Alzheimer’s, possibly due to inappropriate induction of
the cell cycle in post-mitotic neurons. A causal link can
be established between cell cycle activation, neurodegen-
eration, and neuronal loss in vitro, but it has been diffi-
cult to illustrate how cell cycle activation can induce a
slowly developing but ultimately catastrophic effect in
human AD brain. In order to understand the mechan-
isms involved in cell cycle activation and AD pathogen-
esis, we used mice expressing APPV717F and PS1M146L
mutant transgenes. The PS/APP mice develop plaques
at approximately 6 months of age and the APP mice
show plaques at approximately 10-12 months of age.
We found that, similar to human AD, brains from these
mice also show increased expression of some of the cell
cycle regulatory proteins. This was associated with
increased phosphorylation of APP.
In vitro analysis of asynchronously growing H4-APP
cells clearly showed that the phosphorylation of APP
occurs mainly in the cells that are undergoing cell divi-
s i o n .I nt h ei n t e r p h a s e ,c e lls APP phosphorylation was
negligible and was induced as soon as the cells entered
prophase. The experiments with si-cdk2 and pharmaco-
logical inhibitors of the G1/S checkpoint further sup-
ports the conclusion that APP phosphorylation and
processing occurs in a mitosis-specific manner and rein-
forces the idea that inhibition of cell cycle activation at
an early stage may prevent the APP modifications asso-
ciated with the development of AD pathology. APP
phosphorylation is not just mediated by cyclin-depen-
dent kinases. Kinases such as GSK-3b,J N K ,a n dc d k 5
have also been shown to affect Thr668 specific phos-
phorylation of APP. Our studies also showed that this
specific phosphorylation could be inhibited by downre-
gulation of GSK-3b and cdk5. Both GSK-3 and cdk5
have been shown to play roles in the cell cycle and
hence the possibility that these kinases are also behaving
in a cell cycle-dependent manner needs to be estab-
lished [57,58]. Nocodazole-induced mitotic arrest led to
a significant increase in APP phosphorylation compared
to that induced by serum stimulation alone. One of the
reasons for this result could be that the number of
metaphase cells obtained upon treatment with nocoda-
zole (~80% by FACS analysis) is much higher than that
obtained by serum stimulation or taxol treatment
(~40%). The data shown in Figure 8 agrees with this
interpretation; quantitative analysis of the levels of P-
APP and APP showed that while serum stimulation
shows ~30% APP phosphorylation (~40% cells in G2/
M), nocodazole treatment shows ~80%, both of which
correlate with the percent of cells in metaphase. In
addition, nocodazole, being a powerful microtubule
depolymerizing agent, could affect other kinases or
phosphatases and induce APP phosphorylation indepen-
dent of its mitotic arrest-related effects. Treatment of
cells with taxol, another mitotic inhibitor that brings
about cell cycle arrest through microtubule stabilization,
showed only ~40% of cells in metaphase and a P-APP
level of ~30%.
The results presented here strongly indicate that
Thr668 specific phosphorylation on APP is intimately
Figure 12 P-APP co-localization with MPM-2 at centrosomes in
metaphase cells: Asynchronously growing (untreated, top row) and
nocodazole arrested (bottom row) H4-15X cells were
immunostained using the mitosis specific monoclonal antibody
MPM2 and Thr668 P-APP polyclonal antibodies and staining was
visualized using Alexa 488 and 594 fluorophores respectively. The
untreated cells show P-APP localization in centrosomes in the
mitotic cells. In the cells arrested with nocodazole the microtubules
were completely depolymerized and P-APP showed significantly
higher levels of amorphous staining. The nuclei were visualized
using Hoechst stain. Magnification: 63×.
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Page 14 of 20associated with cell cycle activation and that the maxi-
mum phosphorylation occurs in metaphase. This phos-
phorylation transition was associated with increased
APP processing and Ab generation (Figure 13). Thus
the cells do not have to go through a full division to
bring about the modifications in APP suggesting that an
attempt by the cells in AD brain to re-enter cell cycle
could lead to APP phosphorylation and proteolytic clea-
vage without the cells undergoing cell division. The
findings that AD brains show binucleated neurons [59],
as well as aneuploidy and mis-segregation of different
chromosomes [15,61-63] further strengthens the conclu-
sion that neurons in AD brain attempt to undergo DNA
replication and cell division. It is suggested that the cell
cycle regulatory proteins may have a different role in
neurons compared to that in cells undergoing active cell
division; studies show that terminally differentiated neu-
rons use the mechanisms involved in proliferation to
Figure 13 Ab generation is altered in a cell cycle-dependent manner: H4-15X cells were synchronized by serum starvation and stimulated
with serum containing media plus or minus olomoucine, roscovitine, aphidicolin, nocodazole, vinblastine, or taxol. Cell culture supernatants (A
and C) and cell extracts (B and D) were immunoprecipitated and western blotted using 6E10 antibody. Control was performed similarly to the
rest of the samples, except no primary antibody was used in immunoprecipitation assay. Cell culture supernatant showed a time dependent
increase in Ab generation upon serum stimulation (A and C). The extracts showed similar results which was visible only after longer exposure
(D). Panels C and D represent longer exposure of the bottom part of the blots shown in A and B to show the Ab levels in cell extracts. In both
the cases roscovitine treatment was associated with a decrease in the level of secreted and cellular Ab. Secreted APP was not altered in the
supernatant although the level of APP and C-APP fragments are increased in the extracts prepared from nocodazole and vinblastine-arrested
cells. Panel E and F show mean percent of Ab (compared to secreted and full length APP) from 3 independent experiments under different
treatment conditions. Data that showed significant changes are marked using a star (P < 0.05).
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that the complex architecture of mature plastic neurons
makes it impossible for the cells to undergo division
without undergoing damage. The report that centro-
somes localize to the area where the neurites sprout
from and the number of centrosomes determines the
number of neurites [65] suggest that cell cycle activation
may cause asymmetric dynamics on the chromosomes
leading to mis-segregation and formation of aneuploid
cells in the AD brain. The localization of P-APP (data
presented here) and PS1 at the centrosomes [66] suggest
that these molecules may play a role in spindle assembly
and chromosome segregation, and hence the enhanced
expression or mutations of these proteins may cause
chromosome mis-segregation in cells. The data from
our lab support this hypothesis, in which we showed
that expression of APP, Ab, or PS1 lead to chromosome
mis-segregation and aneuploidy [36]. Ab oligomers have
been reported to induce neuronal cell cycle activation
[49,50], and this along with the data presented here,
suggest that Ab generated upon APP phosphorylation
may have a feed forward role in cell cycle activation and
enhanced neurodegeneration in AD brain.
Cell cycle activation not only induced the phosphory-
lation and proteolytic processing of APP, but also
affected the localization of P-APP in cells; mitotic cells
clearly showed centrosome specific localization of P-
APP. It has been proposed that the phosphorylation of
structural or transient components of centrosomes may
affect cell cycle dependent processes such as centrosome
duplication and microtubule nucleation [54]. Thus, in
addition to enhanced proteolytic cleavage, APP phos-
phorylation may influence cell proliferation through its
association with the cell cycle machinery. The co-locali-
zation of P-APP with MPM2, a metaphase protein mar-
ker, further reiterates APP’s role as a growth-promoting
molecule. Therefore, it is possible that high levels of P-
APP may promote proliferation in dividing cells and
centrosome duplication or chromosome mis-segregation
and cell death in post-mitotic neurons. APP’sf u n c t i o n
as a mitogenic molecule is evident from the fact that its
upregulation is associated with cancers of different
organs [67,68]; neurons being postmitotic are fully dif-
ferentiated and undergo apoptosis rather than transfor-
mation upon cell cycle activation. It has been reported
that APP and PS1 associate with other proteins at the
centrosome and localize to centrosomes [69,70]. An N-
terminal APP antibody conjugated to an Alexa fluoro-
phore was used to detect the localization of APP at the
centrosomes. In our hand staining of the cells with the
Ab immunoreactive 6E10 antibody did not show any
significant localization of non-phospho APP to the cen-
trosomes. It is possible that either the antibody or the
techniques we applied to detect the localization are not
strong enough to detect non-phospho APP at the
centrosomes.
Our studies showed that APP and PS/APP mice show
formation of Ab and phosphorylated C-terminal frag-
m e n t so fA P Pa tav e r ye a r l ya g e( 1 . 5m o n t h ) ,a n dt h e
generation of these fragments are increased in an age-
dependent manner. Although this is the case, PS/APP
mice showed clear accumulation of P-APP and Ab in
their brains by 6 months of age whereas APP mice
showed only by 10-12 months. This result suggests that
unless there is an accelerating factor present, the pathol-
ogy in AD develops very slowly and if diagnosed early in
life it can be prevented. The facts that deregulation in
PS1 can induce chromosome miss-segregation and
tumour generation [36,71], and both PS1 and APP
associate with centrosomes, suggest that in addition to
Ab generation, expression of PS1 in APP transgenic
mice may affect cell cycle deregulation and therefore
APP phosphorylation. Whether or not these associates
with early neurodegeneration and neuronal loss
observed in AD brains needs to be determined. Even
t h o u g ht h eP S / A P Pm i c ew eu s e ds h o ws i g n i f i c a n t l y
higher levels of P-APP and accumulation of Ab in to
plaques, unlike in some of the other AD mouse models
such as APP
SL/PS1-KI and 5XFAD mice [68,72,73], we
did not observe any significant neuronal loss. The rea-
son for this is unclear. It is possible that the genetic
background and the transgene expression levels play a
role in plaque load and neuronal loss associated with
different transgenic mouse models. The APP mice we
used do not exhibit as aggressive an AD-like disease as
the ones above, and probably inclusion of an additional
APP mutation in the transgene may be required to
obtain detectable levels of neuronal loss.
Conclusions
In conclusion, cell cycle deregulation may influence the
pathogenesis of AD through multiple pathways: 1)
through phosphorylation and processing of APP to gen-
erate Ab leading to plaque formation, 2) through Ab
and C-terminal fragment of APP inducing tau hyper-
phosphorylation [66,74-76], and 3) through both Ab and
P-APP affecting cell cycle deregulation and contributing
to the unwarranted progression of cell cycle. From the
data presented here it is apparent that an inhibition of
aberrant activation of the cell cycle prior to G1/S check-
point could potentially hinder the modifications in APP
and therefore development of AD pathology. In this
respect, G1/S inhibitors, which are known to protect
neuronal apoptosis in vitro [26,31,32], need to be
explored in vivo for their efficacy in preventing APP
phosphorylation and processing. Once the neurons start
expressing higher levels of cell cycle proteins due to
environmental stress, or inflammation, or high levels of
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development of pathology will take place, and the cells
will succumb to degeneration. The data presented above
and the previous support for the cell cycle hypothesis,
which suggests that the neurons in AD brain enter the
G1 phase of cell cycle [6,7,77], indicate that inhibitors of
the early phases of cell cycle such as those associated
with the G1/S checkpoint may prove to be beneficial in
treating neurodegenerative diseases such as Alzheimer’s.
However, it must be noted that microtubules are essen-
tial for many neuronal functions, and thus any drugs
designed to inhibit APP modifications or Ab generation
should be tested for their effect on microtubule
dynamics both in vitro and in vivo before assuming that
they will be risk-free therapies for AD.
Methods
Ethics Statement
All studies involving animals were done in accord with
the rules and regulations set forth by the University of
South Florida’s Institutional Animal Care and Use Com-
mittee (IACUC). The care for the animals was provided
by the well-established animal care facility at University
o fS o u t hF l o r i d a( U S F ) ,w h i c hi sa c c r e d i t e db yt h e
American Association of Laboratory Animal Care
(AALAC).
Materials
The tissue culture reagents, electrophoresis supplies, and
Alexa fluorphores were purchased from Gibco/Invitro-
gen, Carlsband, CA. Poly-D-Lysine (PDL), a-tubulin
antibody and Hoechst were from Sigma, St. Louis, MO.
Anti-Ab/APP antibody (6E10 raised against Ab1-16)
was from Signet, C-terminal APP antibody was from
Chemicon/Millipore, Thr668 P-APP, MPM-2, and P-
cdc2 antibodies were from Cell Signaling, and cyclin D1,
cyclin E, and E2F1 antibodies were from Santa Cruz
Biotechnology. The reagents for brightfield staining
were purchased from Vector Laboratories. Enhanced
chemiluminescence (ECL) reagent was from Pierce Bio-
technology Inc., Rockford, IL. H4 neuroglioma cells
overexpressing WT-APP (H4-APP) was a kind gift from
Dr. Todd Golde (Mayo clinic, Jacksonville, Florida).
Transgenic Mice
Heterozygous PDGF-hAPP (V717F) mice (Swiss-
Webster × C57BL/6) were crossed with PDGF-hPS1
(M146L) heterozygotes (Swiss-Webster × C57BL/6) to
generate mice with an APP
+/-,P S 1
+/- genotype. All off-
spring were screened by PCR to verify the expression of
APP and PS1 gene [78,79]. The APP mutant mice
develop many of the pathological hallmarks of AD,
including neuritic plaques (appear at around 10-12
months of age), and cognitive deficits in an age-
dependent manner, and the expression of mutant PS1 in
these mice accelerates the pathology development signif-
icantly (plaques are visible as early as 4-6 months of
age) (Figure 7D). In the current study we used these
transgenic and age-matched non-transgenic (Ntg) mice.
Mice were anesthetized using Nembutal (10 mg/kg body
weight) and perfused with saline solution. The brains
were dissected out and half of each brain was immersion
fixed with 4% para-formaldehyde and the other half was
used for protein extraction. For protein extraction,
brains were homogenized in Hepes lysis buffer (50 mM
HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton
X-100, 5 mM MgCl2, 1 mM EGTA, 20 mM NaF, 2 mM
Na3VO4, and protease inhibitors (Roche)). Samples were
centrifuged at 14,000 rpm for 30 min and equal
amounts of proteins were used for western blot analysis.
The brains were processed as described before for
immunohistochemical analysis [80]. Brain sections were
made using a freezing stage sliding microtome and
stored at 4°C in phosphate buffered saline (PBS) con-
taining sodium azide (0.02%) for immunohistochemical
analysis.
Immunostaining
This was done following the established protocols
[80,81]. Briefly, H4-15X cells cultured in 8-chamber tis-
sue culture slides coated with PDL were treated with or
without different inhibitors of the cell cycle for 18 hr;
roscovitine (20 μM) as G1/S inhibitor, aphidicolin (5 μg/
ml) as S-phase inhibitor, nocodazole or vinblastine (100
ng/ml or 10 μM respectively) or taxol (placitaxel, 100
ng/ml) as mitotic inhibitor. At the end of the treatment,
cells were fixed with 4% para-formaldehyde and staining
was performed using the appropriate antibodies. Stain-
ing was analyzed under a Zeiss microscope using the
AxioVision Rel 4.8 software. Centrosome specific stain-
ing of P-APP in H4-APP cells was confirmed by confo-
cal microscopy under an Olympus imaging system using
Fluoview FV1000 ver.1.7 software.
For immunostaining analysis of the brain sections, sec-
tions were mounted onto superfrost slides, and non-spe-
cific binding was blocked by incubating with 10%
n o r m a lg o a ts e r u m( N G S ) / T B S Tf o r2h ra tr o o mt e m -
perature. Sections were then incubated with appropriate
dilutions of the primary antibody (APP (6E10), Thr668-
P-APP, cyclin D1, cyclin E, E2F1, and P-cdc2 antibodies)
in 1% BSA/TBST overnight at 4°C in a humidified
chamber. After thorough washing, the sections were
incubated with biotinylated mouse or rabbit secondary
antibodies for 1 hr at room temperature and developed
following the manufacturer’s protocol with the DAB kit
from Vector laboratories. The staining was visualized
using a Nikon E1000 microscope using Image-Pro Plus
software. In the case of fluorescent labeling, after
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were incubated with Alexa 488 or 594 fluorophores for
2 hr at room temperature protected from light. Sections
were washed and nuclei were counter stained using
Hoechst 33342 and washed again before mounting using
aqueous Gel/Mount. Sections were stained with second-
ary antibody alone to determine non-specific binding of
antibodies to the tissue (data not shown). The results
were analysed under a Zeiss microscope using the Axio-
Vision Rel 4.8 software. The signal intensity of the
images was determined by Image J, image processing
and analysis program [32]. Adjacent sections from at
least 3 independent mice expressing different transgenes
were stained using the antibody of interest. Prior to
measurement, the images were converted to 8-bit grays-
cale and the threshold of all the images from each set of
experiments was adjusted to the same level. This keeps
the sample-to-sample variation minimal. The intensity
obtained with Hoechst staining was used as a normaliz-
ing control for each section.
Immunoprecipitation and Western blot analysis
H4-15X cells were cultured in OPTI-MEM containing
10% FBS and 50 μg/ml hygromycin in 100 mm culture
dishes overnight and serum starved for 48 to 72 hr.
Serum stimulation of the cells was done in the presence
or absence of different pharmacological inhibitors for
the indicated time periods. Cell culture supernatants
and cell lysates (made in Hepes lysis buffer) were immu-
noprecipitated using 6E10 antibody and analyzed using
the same antibody to detect secreted and cellular levels
of Ab. In the case of brain extracts, equal amounts of
protein were boiled with Tricine sample buffer and
PAGE and western-immunoblot analysis was performed
using appropriate antibodies. For quantification, western
blot images on the X-ray film were scanned and densi-
tometric analysis was performed using the Image J,
image processing and analysis tool after selecting and
plotting the bands of interest.
siRNA transfection of H4-APP cells
We obtained Silencer validated siRNA to cdk2 (locus
ID: 1017) from (Ambion, Inc. Applied Biosystems),
siRNA to cdk5 from Santa Cruz Biotechnology and
siRNA to GSK-3ab from Invitrogen. The siRNA was
used at the indicated concentrations and transfected
using oligofectamine (Invitrogen) using OPTI-MEM
without serum. 6 hr after transfection the media was
replenished with an equal volume of OPTI-MEM con-
taining 2X serum and cultured for 24 to 48 hr. At the
end of the time period cells were harvested in sample
buffer and analyzed by western blot for downregulation
of the kinases using the corresponding kinase antibody
and phosphorylation of APP by Thr668 P-APP antibody.
Statistical analysis was performed using Student’st -
Test.
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AD: Alzheimer’s disease; APP: amyloid precursor protein; PS: presenilin;
Thr668 P-APP: APP phosphorylated at Threonine 668; C-APP: C-terminal APP;
P-C-APP: phosphorylated C-APP; cdk: cyclin-dependent kinase.
Acknowledgements
We would like to thank the following individuals at University of South
Florida; Dr. Tiffany Hughes and Michelle Norden for help with breeding and
genotyping of the transgenic mice, Dr. Byeong Cha with confocal image
analysis, Dr. Karoly Szekeres for help with the FACS analysis. We are grateful
to Dr. Todd Golde (Mayo Clinic, Jacksonville, FL) for kindly providing the H4
neuroglioma cells overexpressing APP. This work was supported by grants
from the Alzheimer’s association (IIRG-08-90842 to JP), NIH-NIA
(1R21AG031429-01A2 to JP and AG25711 to HP) and funds from the USF
Health Byrd Alzheimer’s Institute and the Department of Molecular Medicine
at USF, Tampa.
Author details
1Department of Molecular Medicine, University of South Florida, 12901 Bruce
B. Downs Blvd., Tampa, FL-33612, USA.
2USF Health Byrd Alzheimer’s
Institute, 4001 E. Fletcher Ave., Tampa, FL-33613, USA.
3Suncoast
Gerontology Center, USF Health Byrd Alzheimer’s Institute, 4001 E. Fletcher
Ave., Tampa, FL-33613, USA.
4Florida Alzheimer’s Disease Research Center,
USF Health Byrd Alzheimer’s Institute, 4001 E. Fletcher Ave., Tampa, FL-33613,
USA.
Authors’ contributions
JP designed and carried out all of the in vitro studies and part of the in vivo
studies, ML was instrumental in the cell cycle analysis of transgenic brains,
LH helped with western blot analysis of brain extracts, and HP provided the
transgenic mice and helped with scientific discussions. All authors have read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 January 2011 Accepted: 23 November 2011
Published: 23 November 2011
References
1. Wong CW, Quaranta V, Glenner GG: Neuritic plaques and cerebrovascular
amyloid in Alzheimer disease are antigenically related. Proceedings of the
National Academy of Sciences of the United States of America 1985,
82(24):8729-8732.
2. Kosik KS, Joachim CL, Selkoe DJ: Microtubule-associated protein tau (tau)
is a major antigenic component of paired helical filaments in Alzheimer
disease. Proceedings of the National Academy of Sciences of the United States
of America 1986, 83(11):4044-4048.
3. Nukina N, Kosik KS, Selkoe DJ: Recognition of Alzheimer paired helical
filaments by monoclonal neurofilament antibodies is due to
crossreaction with tau protein. Proceedings of the National Academy of
Sciences of the United States of America 1987, 84(10):3415-3419.
4. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA: Abnormal expression
of the cell cycle regulators P16 and CDK4 in Alzheimer’s disease. The
American journal of pathology 1997, 150(6):1933-1939.
5. Vincent I, Jicha G, Rosado M, Dickson DW: Aberrant expression of mitotic
cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer’s disease
brain. J Neurosci 1997, 17(10):3588-3598.
6. Vincent I, Rosado M, Davies P: Mitotic mechanisms in Alzheimer’s
disease? Journal of Cell Biology 1996, 132(3):413-425.
7. Arendt T, Rodel L, Gartner U, Holzer M: Expression of the cyclin-
dependent kinase inhibitor p16 in Alzheimer’s disease. Neuroreport 1996,
7(18):3047-3049.
8. Nagy Z, Esiri MM, Smith AD: Expression of cell division markers in the
hippocampus in Alzheimer’s disease and other neurodegenerative
conditions. Acta neuropathologica 1997, 93(3):294-300.
Judge et al. Molecular Neurodegeneration 2011, 6:80
http://www.molecularneurodegeneration.com/content/6/1/80
Page 18 of 209. Lee EY, Hu N, Yuan SS, Cox LA, Bradley A, Lee WH, Herrup K: Dual roles of
the retinoblastoma protein in cell cycle regulation and neuron
differentiation. Genes & development 1994, 8(17):2008-2021.
10. Freeman RS, Estus S, Johnson EM Jr: Analysis of cell cycle-related gene
expression in postmitotic neurons: selective induction of Cyclin D1
during programmed cell death. Neuron 1994, 12(2):343-355.
11. Herrup K, Busser JC: The induction of multiple cell cycle events precedes
target-related neuronal death. Development (Cambridge, England) 1995,
121(8):2385-2395.
12. Feddersen RM, Clark HB, Yunis WS, Orr HT: In vivo viability of postmitotic
Purkinje neurons requires pRb family member function. Molecular and
cellular neurosciences 1995, 6(2):153-167.
13. Kranenburg O, van der Eb AJ, Zantema A: Cyclin D1 is an essential
mediator of apoptotic neuronal cell death. The EMBO journal 1996,
15(1):46-54.
14. Nagy Z, Esiri MM: Neuronal cyclin expression in the hippocampus in
temporal lobe epilepsy. Experimental neurology 1998, 150(2):240-247.
15. Arendt T: Alzheimer’s disease as a loss of differentiation control in a
subset of neurons that retain immature features in the adult brain.
Neurobiology of aging 2000, 21(6):783-796.
16. Hoozemans JJ, Bruckner MK, Rozemuller AJ, Veerhuis R, Eikelenboom P,
Arendt T: Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2
(COX-2) in pyramidal neurons in Alzheimer disease temporal cortex.
Journal of neuropathology and experimental neurology 2002, 61(8):678-688.
17. Herrup K, Arendt T: Re-expression of cell cycle proteins induces neuronal
cell death during Alzheimer’s disease. J Alzheimers Dis 2002, 4(3):243-247.
18. Copani A, Guccione S, Giurato L, Caraci F, Calafiore M, Sortino MA,
Nicoletti F: The cell cycle molecules behind neurodegeneration in
Alzheimer’s disease: perspectives for drug development. Current
medicinal chemistry 2008, 15(24):2420-2432.
19. Raina AK, Pardo P, Rottkamp CA, Zhu X, Pereira-Smith OM, Smith MA:
Neurons in Alzheimer disease emerge from senescence. Mechanisms of
ageing and development 2001, 123(1):3-9.
20. Smith TW, Lippa CF: Ki-67 immunoreactivity in Alzheimer’s disease and
other neurodegenerative disorders. Journal of neuropathology and
experimental neurology 1995, 54(3):297-303.
21. Vincent I, Zheng JH, Dickson DW, Kress Y, Davies P: Mitotic
phosphoepitopes precede paired helical filaments in Alzheimer’s
disease. Neurobiology of aging 1998, 19(4):287-296.
22. Busser J, Geldmacher DS, Herrup K: Ectopic cell cycle proteins predict the
sites of neuronal cell death in Alzheimer’s disease brain. J Neurosci 1998,
18(8):2801-2807.
23. Malik B, Currais A, Andres A, Towlson C, Pitsi D, Nunes A, Niblock M,
Cooper J, Hortobagyi T, Soriano S: Loss of neuronal cell cycle control as a
mechanism of neurodegeneration in the presenilin-1 Alzheimer’s
disease brain. Cell cycle (Georgetown, Tex 2008, 7(5):637-646.
24. Farinelli SE, Greene LA: Cell cycle blockers mimosine, ciclopirox, and
deferoxamine prevent the death of PC12 cells and postmitotic
sympathetic neurons after removal of trophic support. J Neurosci 1996,
16(3):1150-1162.
25. Park DS, Levine B, Ferrari G, Greene LA: Cyclin dependent kinase inhibitors
and dominant negative cyclin dependent kinase 4 and 6 promote
survival of NGF-deprived sympathetic neurons. J Neurosci 1997,
17(23):8975-8983.
26. Park DS, Morris EJ, Padmanabhan J, Shelanski ML, Geller HM, Greene LA:
Cyclin-dependent kinases participate in death of neurons evoked by
DNA-damaging agents. The Journal of cell biology 1998, 143(2):457-467.
27. Giovanni A, Keramaris E, Morris EJ, Hou ST, O’Hare M, Dyson N,
Robertson GS, Slack RS, Park DS: E2F1 mediates death of B-amyloid-
treated cortical neurons in a manner independent of p53 and
dependent on Bax and caspase 3. The Journal of biological chemistry 2000,
275(16):11553-11560.
28. Konishi Y, Bonni A: The E2F-Cdc2 cell-cycle pathway specifically mediates
activity deprivation-induced apoptosis of postmitotic neurons. J Neurosci
2003, 23(5):1649-1658.
29. Kruman II, Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, Chrest FJ,
Emokpae R Jr, Gorospe M, Mattson MP: Cell cycle activation linked to
neuronal cell death initiated by DNA damage. Neuron 2004,
41(4):549-561.
30. Verdaguer E, Jorda EG, Stranges A, Canudas AM, Jimenez A, Sureda FX,
Pallas M, Camins A: Inhibition of CDKs: a strategy for preventing kainic
acid-induced apoptosis in neurons. Annals of the New York Academy of
Sciences 2003, 1010:671-674.
31. Padmanabhan J, Park DS, Greene LA, Shelanski ML: Role of cell cycle
regulatory proteins in cerebellar granule neuron apoptosis. J Neurosci
1999, 19(20):8747-8756.
32. Padmanabhan J, Brown K, Shelanski ML: Cell cycle inhibition and
retinoblastoma protein overexpression prevent Purkinje cell death in
organotypic slice cultures. Developmental neurobiology 2007, 67(6):818-826.
33. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science (New York,
NY 2002, 297(5580):353-356.
34. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD,
Hardy J, Hutton M, Kukull W, et al: Secreted amyloid beta-protein similar
to that in the senile plaques of Alzheimer’s disease is increased in vivo
by the presenilin 1 and 2 and APP mutations linked to familial
Alzheimer’s disease. Nature medicine 1996, 2(8):864-870.
35. Copani A, Melchiorri D, Caricasole A, Martini F, Sale P, Carnevale R,
Gradini R, Sortino MA, Lenti L, De Maria R, et al: Beta-amyloid-induced
synthesis of the ganglioside GD3 is a requisite for cell cycle
reactivation and apoptosis in neurons. J Neurosci 2002,
22(10):3963-3968.
36. Boeras DI, Granic A, Padmanabhan J, Crespo NC, Rojiani AM, Potter H:
Alzheimer’s presenilin 1 causes chromosome missegregation and
aneuploidy. Neurobiology of aging 2008, 29(3):319-328.
37. Geller LN, Potter H: Chromosome missegregation and trisomy 21
mosaicism in Alzheimer’s disease. Neurobiology of disease 1999,
6(3):167-179.
38. Gartner U, Bruckner MK, Krug S, Schmetsdorf S, Staufenbiel M, Arendt T:
Amyloid deposition in APP23 mice is associated with the expression of
cyclins in astrocytes but not in neurons. Acta neuropathologica 2003,
106(6):535-544.
39. Yang Y, Varvel NH, Lamb BT, Herrup K: Ectopic cell cycle events link
human Alzheimer’s disease and amyloid precursor protein transgenic
mouse models. J Neurosci 2006, 26(3):775-784.
40. Muresan Z, Muresan V: A phosphorylated, carboxy-terminal fragment of
beta-amyloid precursor protein localizes to the splicing factor
compartment. Human molecular genetics 2004, 13(5):475-488.
41. Muresan Z, Muresan V: The amyloid-beta precursor protein is
phosphorylated via distinct pathways during differentiation, mitosis,
stress, and degeneration. Molecular biology of the cell 2007,
18(10):3835-3844.
42. Arendt T: Synaptic plasticity and cell cycle activation in neurons are
alternative effector pathways: the ‘Dr. Jekyll and Mr. Hyde concept’ of
Alzheimer’s disease or the yin and yang of neuroplasticity. Progress in
neurobiology 2003, 71(2-3):83-248.
43. Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, Jeong YH, Lee JP, Park CH,
Kim S, Baik TK, et al: Phosphorylation of amyloid precursor protein (APP)
at Thr668 regulates the nuclear translocation of the APP intracellular
domain and induces neurodegeneration. Molecular and cellular biology
2006, 26(11):4327-4338.
44. Suzuki T, Nakaya T: Regulation of amyloid beta-protein precursor by
phosphorylation and protein interactions. The Journal of biological
chemistry 2008, 283(44):29633-29637.
45. Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, Greengard P: Cell
cycle-dependent regulation of the phosphorylation and metabolism of
the Alzheimer amyloid precursor protein. The EMBO journal 1994,
13(5):1114-1122.
46. Rebelo S, Vieira SI, Esselmann H, Wiltfang J, da Cruz e Silva EF, da Cruz e
Silva OA: Tyrosine 687 phosphorylated Alzheimer’s amyloid precursor
protein is retained intracellularly and exhibits a decreased turnover rate.
Neurodegener Dis 2007, 4(2-3):78-87.
47. Vieira SI, Rebelo S, Domingues SC, da Cruz e Silva EF, da Cruz e Silva OA:
S655 phosphorylation enhances APP secretory traffic. Mol Cell Biochem
2009, 328(1-2):145-154.
48. Vieira SI, Rebelo S, Esselmann H, Wiltfang J, Lah J, Lane R, Small SA,
Gandy S, da Cruz ESEF, da Cruz ESOA: Retrieval of the Alzheimer’s
amyloid precursor protein from the endosome to the TGN is S655
phosphorylation state-dependent and retromer-mediated. Mol
Neurodegener 2010, 5:40.
49. Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS: Involvement of
cell cycle elements, cyclin-dependent kinases, pRb, and E2F × DP, in B-
Judge et al. Molecular Neurodegeneration 2011, 6:80
http://www.molecularneurodegeneration.com/content/6/1/80
Page 19 of 20amyloid-induced neuronal death. The Journal of biological chemistry 1999,
274(27):19011-19016.
50. Varvel NH, Bhaskar K, Patil AR, Pimplikar SW, Herrup K, Lamb BT: Abeta
oligomers induce neuronal cell cycle events in Alzheimer’s disease. J
Neurosci 2008, 28(43):10786-10793.
51. Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ,
Lemere CA: Temporal accrual of complement proteins in amyloid
plaques in Down’s syndrome with Alzheimer’s disease. The American
journal of pathology 2000, 156(2):489-499.
52. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M,
Delcros JG, Moulinoux JP: Biochemical and cellular effects of roscovitine,
a potent and selective inhibitor of the cyclin-dependent kinases cdc2,
cdk2 and cdk5. European journal of biochemistry/FEBS 1997, 243(1-
2):527-536.
53. Glab N, Labidi B, Qin LX, Trehin C, Bergounioux C, Meijer L: Olomoucine,
an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the
G1 to S and G2 to M cell cycle transitions. FEBS letters 1994,
353(2):207-211.
54. Vandre DD, Centonze VE, Peloquin J, Tombes RM, Borisy GG: Proteins of
the mammalian mitotic spindle: phosphorylation/dephosphorylation of
MAP-4 during mitosis. Journal of cell science 1991, 98(Pt 4):577-588.
55. Jinno S, Araki K, Matsumoto Y, Suh YH, Yamamoto T: Selective apoptosis
induction in the hippocampal mossy fiber pathway by exposure to
CT105, the C-terminal fragment of Alzheimer’s amyloid precursor
protein. Brain research 2009, 1249:68-78.
56. McShea A, Wahl AF, Smith MA: Re-entry into the cell cycle: a mechanism
for neurodegeneration in Alzheimer disease. Medical hypotheses 1999,
52(6):525-527.
57. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M,
Stacey DW: Phosphorylation of cyclin D1 at Thr 286 during S phase
leads to its proteasomal degradation and allows efficient DNA synthesis.
Oncogene 2005, 24(16):2599-2612.
58. Zhang J, Cicero SA, Wang L, Romito-Digiacomo RR, Yang Y, Herrup K:
Nuclear localization of Cdk5 is a key determinant in the postmitotic
state of neurons. Proceedings of the National Academy of Sciences of the
United States of America 2008, 105(25):8772-8777.
59. Zhu X, Siedlak SL, Wang Y, Perry G, Castellani RJ, Cohen ML, Smith MA:
Neuronal binucleation in Alzheimer disease hippocampus.
Neuropathology and applied neurobiology 2008, 34(4):457-465.
60. Arendt T: Synaptic degeneration in Alzheimer’s disease. Acta
neuropathologica 2009, 118(1):167-179.
61. Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T: Aneuploidy
and DNA replication in the normal human brain and Alzheimer’s
disease. J Neurosci 2007, 27(26):6859-6867.
62. Iourov IY, Vorsanova SG, Liehr T, Yurov YB: Aneuploidy in the normal,
Alzheimer’s disease and ataxia-telangiectasia brain: differential
expression and pathological meaning. Neurobiology of disease 2009,
34(2):212-220.
63. Zekanowski C, Wojda U: Aneuploidy, chromosomal missegregation, and
cell cycle reentry in Alzheimer’s disease. Acta neurobiologiae experimentalis
2009, 69(2):232-253.
64. Schmetsdorf S, Gartner U, Arendt T: Expression of cell cycle-related
proteins in developing and adult mouse hippocampus. Int J Dev Neurosci
2005, 23(1):101-112.
65. de Anda FC, Pollarolo G, Da Silva JS, Camoletto PG, Feiguin F, Dotti CG:
Centrosome localization determines neuronal polarity. Nature 2005,
436(7051):704-708.
66. Ferreira A, Lu Q, Orecchio L, Kosik KS: Selective phosphorylation of adult
tau isoforms in mature hippocampal neurons exposed to fibrillar A beta.
Molecular and cellular neurosciences 1997, 9(3):220-234.
67. Hansel DE, Rahman A, Wehner S, Herzog V, Yeo CJ, Maitra A: Increased
expression and processing of the Alzheimer amyloid precursor protein
in pancreatic cancer may influence cellular proliferation. Cancer research
2003, 63(21):7032-7037.
68. Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N,
Vingtdeux V, van de Steeg E, Ret G, Canton T, et al: Massive CA1/2
neuronal loss with intraneuronal and N-terminal truncated Abeta42
accumulation in a novel Alzheimer transgenic model. The American
journal of pathology 2004, 165(4):1289-1300.
69. Nizzari M, Venezia V, Bianchini P, Caorsi V, Diaspro A, Repetto E, Thellung S,
Corsaro A, Carlo P, Schettini G, et al: Amyloid precursor protein and
Presenilin 1 interaction studied by FRET in human H4 cells. Annals of the
New York Academy of Sciences 2007, 1096:249-257.
70. Nizzari M, Venezia V, Repetto E, Caorsi V, Magrassi R, Gagliani MC, Carlo P,
Florio T, Schettini G, Tacchetti C, et al: Amyloid precursor protein and
Presenilin1 interact with the adaptor GRB2 and modulate ERK 1, 2
signaling. The Journal of biological chemistry 2007, 282(18):13833-13844.
71. Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, Koo EH, Wu X,
Zheng H: Loss of presenilin 1 is associated with enhanced beta-catenin
signaling and skin tumorigenesis. Proceedings of the National Academy of
Sciences of the United States of America 2001, 98(19):10863-10868.
72. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A,
Ohno M, Disterhoft J, Van Eldik L, et al: Intraneuronal beta-amyloid
aggregates, neurodegeneration, and neuron loss in transgenic mice
with five familial Alzheimer’s disease mutations: potential factors in
amyloid plaque formation. J Neurosci 2006, 26(40):10129-10140.
73. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, Disterhoft JF,
Vassar R: BACE1 gene deletion prevents neuron loss and memory
deficits in 5XFAD APP/PS1 transgenic mice. Neurobiology of disease 2007,
26(1):134-145.
74. Greenberg SM, Koo EH, Selkoe DJ, Qiu WQ, Kosik KS: Secreted beta-
amyloid precursor protein stimulates mitogen-activated protein kinase
and enhances tau phosphorylation. Proceedings of the National Academy
of Sciences of the United States of America 1994, 91(15):7104-7108.
75. Oster-Granite ML, McPhie DL, Greenan J, Neve RL: Age-dependent
neuronal and synaptic degeneration in mice transgenic for the C
terminus of the amyloid precursor protein. J Neurosci 1996,
16(21):6732-6741.
76. Xu Y, Kim HS, Joo Y, Choi Y, Chang KA, Park CH, Shin KY, Kim S, Cheon YH,
Baik TK, et al: Intracellular domains of amyloid precursor-like protein 2
interact with CP2 transcription factor in the nucleus and induce
glycogen synthase kinase-3beta expression. Cell death and differentiation
2007, 14(1):79-91.
77. Woods J, Snape M, Smith MA: The cell cycle hypothesis of Alzheimer’s
disease: suggestions for drug development. Biochimica et biophysica acta
2007, 1772(4):503-508.
78. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L,
Harigaya Y, Yager D, et al: Increased amyloid-beta42(43) in brains of mice
expressing mutant presenilin 1. Nature 1996, 383(6602):710-713.
79. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C,
Carr T, Clemens J, Donaldson T, Gillespie F, et al: Alzheimer-type
neuropathology in transgenic mice overexpressing V717F beta-amyloid
precursor protein. Nature 1995, 373(6514):523-527.
80. Padmanabhan J, Levy M, Dickson DW, Potter H: Alpha1-antichymotrypsin,
an inflammatory protein overexpressed in Alzheimer’s disease brain,
induces tau phosphorylation in neurons. Brain 2006, 129(Pt
11):3020-3034.
81. Padmanabhan J: Detection of histone H3 phosphorylation in cultured
cells and tissue sections by immunostaining. Methods in molecular biology
(Clifton, NJ 2009, 523:311-322.
doi:10.1186/1750-1326-6-80
Cite this article as: Judge et al.: Mitosis-specific phosphorylation of
amyloid precursor protein at Threonine 668 leads to its altered
processing and association with centrosomes. Molecular
Neurodegeneration 2011 6:80.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Judge et al. Molecular Neurodegeneration 2011, 6:80
http://www.molecularneurodegeneration.com/content/6/1/80
Page 20 of 20